An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study

An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study

Anthracycline-based regimens with or without anti-human epidermal growth factor receptor (HER) 2 agents such as trastuzumab are effective in breast cancer treatment. Nevertheless, heart failure (HF) has become a significant side effect of these regimens. This study aimed to investigate the incidence...

Full description

Bibliographic Details
Main Authors: Jukapun Yoodee, Aumkhae Sookprasert, Phitjira Sanguanboonyaphong, Suthan Chanthawong, Manit Seateaw, Suphat Subongkot
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Clinics and Practice
Subjects:
anthracyclines
breast cancer
cardiotoxicity
Online Access:https://www.mdpi.com/2039-7283/11/3/64

Similar Items

Similar Items